Biogen Idec Inc. reported 7 more cases of a rare brain infection among multiple sclerosis patients taking Tysabri, sold with Elan Corp. bringing the total number of affected patients to 102 as of March 4.
The Weston, Mass., biotech company reported that one more of those patients has died, bringing the total to 21. The cases of the infection--known as progressive multifocal leukoencephalopathy, or PML--are closely watched as the MS market becomes increasingly competitive.
The drug is generally regarded as highly effective, but mostly used for patients that have stopped responding to other drugs or have aggressive cases of the disease. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905
